We further investigated the potential antitumor effect of the combination of dasatinib and BRAF inhibitors first in BRAFV600E CRC HT29 CDX models (Fig. 6a, b) and then in two PDX mouse models (Fig. 6c, d). The gene discussed is BRAF; the disease is colorectal carcinoma.